Arimidex Observational: Reason for and Effect of Change From Tamoxifen

Arimidex: Reason for and Effect of Change From Tamoxifen

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00246961

Acronym

ARREST

Enrollment

200

Registered

2005-11-01

Start date

2004-07-31

Completion date

Unknown

Last updated

2007-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Adjuvant

Brief summary

The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Postmenopausal * Hormone sensitive breast cancer * Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago

Exclusion criteria

* Visceral metastases * Patients with signs of progression at the moment of changing therapy * Patients who have used other endocrine treatments for breast cancer besides tamoxifen

Countries

Netherlands

Outcome results